title: [Swallowing after chemotherapy and radiotherapy for laryngeal and hypopharyngeal carcinomas].
abstract: The main goals of the larynx preservation protocol are eradication of cancer and preservation of a functional larynx with maintenance of respiration, phonation and swallowing. Few studies, however have addressed functional outcomes.
  
  
  OBJECTIVE
  Functional evaluation of oropharyngeal swallowing in patients enrolled in a larynx preservation protocol at the Hospital do Câncer AC Camargo.
  
  
  METHODS
  Evaluation of swallowing was performed by videofluoroscopy in 31 patients, focusing on: oropharyngeal motility disorders, stasis, laryngeal penetration, aspiration and severity of dysphagia.
  
  
  RESULTS
  Swallowing analysis: 5 patients showed inefficient bolus preparation, 14 had changes in the bolus propulsion; 23 patients had a reduced laryngeal elevation, 26 presented with stasis in the vallecula and 14 with stasis in hypopharynx. Nine patients presented silent aspiration. We detected functional swallowing in 11 patients; mild dysphagia in 7; mild/moderate in 7; moderate in 3 and severe dysphagia in 3.
  
  
  CONCLUSIONS
  Larynx preservation results in changes of swallowing, ranging in their majority from discrete to moderate. Some patients, however, developed severe dysphagia, and oral feeding was not possible.
authors.affiliation: Departamento de Cirurgia de Cabeça e Pescoço e Otorrinolaringologia, Centro de Tratamento e Pesquisa, Hospital do Câncer AC Camargo, São Paulo, SP.
authors.forename: Andréa Bizarria
authors.initials: AB
authors.lastname: Cintra
authors.forename: Luciana Passuello do
authors.initials: LP
authors.lastname: Vale
authors.forename: Olavo
authors.initials: O
authors.lastname: Feher
authors.forename: Inês Nobuko
authors.initials: IN
authors.lastname: Nishimoto
authors.forename: Luiz Paulo
authors.initials: LP
authors.lastname: Kowalski
authors.forename: Elisabete Carrara de
authors.initials: EC
authors.lastname: Angelis
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000503:physiopathology* / Q000532:radiotherapy; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003680:Deglutition Disorders / Q000209:etiology / Q000503:physiopathology*; D004415:Dyspepsia / Q000209:etiology; D005260:Female; D005471:Fluoroscopy; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology* / Q000532:radiotherapy; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014741:Video Recording
chemical_list: D000970:Antineoplastic Agents; C495179:Pacliex; D017239:Paclitaxel; D002945:Cisplatin